Responses

Download PDFPDF
Frequency of the TMPRSS2:ERG gene fusion is increased in moderate to poorly differentiated prostate cancers
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests

PLEASE NOTE:

  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    TMPRSS2-ERG in Localized Parostate Cancer

    Dear Editor

    The TMPRSS2-ERG has been described in several prostate cancer patients' cohorts. The article by Ashish et al. describes the frequency of this fusion in another patient cohort. It further demonstrates that the frequency of TMPRSS2-ERG is increased in moderate to poorly differentiated tumors. We would like to congratulate the authors on their interesting study and advocate that more work still has to be carrie...

    Show More
    Conflict of Interest:
    None declared.